ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,238.30
-0.05%
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs Yen
155.866
0.07%
Brent Oil
83.615
0.02%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Prana Biotechnology Ltd ADS (PRAN)

  7. Prana Biotechnology Ltd ADS (PRAN) ニュース

PRAN

Prana Biotechnology Ltd ADS (PRAN)

Prana Biotechnology Ltd ADS
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:PRAN
日付受信時刻ニュースソース見出しコード企業名
2019/01/3123 : 01Business WirePrana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System AtrophyNASDAQ:PRANPrana Biotechnology Ltd ADS
2019/01/0221 : 00PR Newswire (US)Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in PranaNASDAQ:PRANPrana Biotechnology Ltd ADS
2018/10/0512 : 47Business WirePrana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSANASDAQ:PRANPrana Biotechnology Ltd ADS
2018/09/0419 : 22Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PRANPrana Biotechnology Ltd ADS
2018/07/0909 : 15Business WirePBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement DisordersNASDAQ:PRANPrana Biotechnology Ltd ADS
2018/07/0410 : 38Business WireFirst Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian DiseasesNASDAQ:PRANPrana Biotechnology Ltd ADS
2018/06/1409 : 55Business WirePrana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian DiseasesNASDAQ:PRANPrana Biotechnology Ltd ADS
2017/07/1822 : 00Business WirePrana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal NeuropathologyNASDAQ:PRANPrana Biotechnology Ltd ADS
2017/07/0522 : 00Business WirePrana's PBT434 Lowers Alpha-Synuclein and Prevents NeurodegenerationNASDAQ:PRANPrana Biotechnology Ltd ADS
2017/06/0521 : 30Business WirePrana Appoints David Stamler as Chief Medical Officer to Lead Clinical DevelopmentNASDAQ:PRANPrana Biotechnology Ltd ADS
2016/10/1900 : 00Business WireNew Data from Reach2HD Trial Presented at American Neurological Association Annual MeetingNASDAQ:PRANPrana Biotechnology Ltd ADS
2016/07/2801 : 22Business WirePrana Alzheimer's disease data features at world leading conferenceNASDAQ:PRANPrana Biotechnology Ltd ADS
2016/04/1121 : 00Business WirePrana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA SubmissionNASDAQ:PRANPrana Biotechnology Ltd ADS
2016/02/2622 : 00Business WirePrana Biotechnology Half Year Investor ReportNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/11/1623 : 00Business WirePrana Chief Scientific Advisor Receives Smithsonian American Ingenuity AwardNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/11/0922 : 00Business WirePrana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price RequirementNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/08/2721 : 00Business WirePrana Reports FY15 Financial ResultsNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/07/2422 : 00PR Newswire (US)Technical Report on Drug Manufacturers - Other Stocks -- Synergy Pharma, Teva Pharma, Orexigen Therapeutics, Prana Biotechnol...NASDAQ:PRANPrana Biotechnology Ltd ADS
2015/07/0112 : 58Business WirePrana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension TrialNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/06/0202 : 21Business WireLa Commission européenne approuve la désignation orpheline pour le PBT2 dans le cadre de la maladie de HuntingtonNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/06/0200 : 20Business WireEuropäische Kommission gewährt PBT2 Orphan-Status für Chorea HuntingtonNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/06/0122 : 00Business WireEuropean Commission Approves PBT2 Orphan Designation for Huntington’s DiseaseNASDAQ:PRANPrana Biotechnology Ltd ADS
2015/04/2812 : 22Business WirePBT2 Recommended for Orphan Designation in EuropeNASDAQ:PRANPrana Biotechnology Ltd ADS
2014/11/2001 : 00Business WireThe Lancet Neurology Publishes Prana's Huntington Disease TrialNASDAQ:PRANPrana Biotechnology Ltd ADS
2014/09/0522 : 49Dow Jones NewsU.S. Hot Stocks: Hot Stocks to WatchNASDAQ:PRANPrana Biotechnology Ltd ADS
2014/09/0520 : 45PR Newswire (US)Prana receives FDA Orphan Drug Designation for PBT2 for Huntington DiseaseNASDAQ:PRANPrana Biotechnology Ltd ADS
2014/07/1805 : 10PR Newswire (US)Prana Alzheimer's disease Development Program updateNASDAQ:PRANPrana Biotechnology Ltd ADS
2014/05/1620 : 39Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PRANPrana Biotechnology Ltd ADS
2014/05/1420 : 42Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PRANPrana Biotechnology Ltd ADS
2014/05/1420 : 30PR Newswire (US)World leader in movement disorders Professor Ira Shoulson joins Prana BoardNASDAQ:PRANPrana Biotechnology Ltd ADS
 Showing the most relevant articles for your search:NASDAQ:PRAN

最近閲覧した銘柄

BIT
F39593
Vontobel Financial Produ...
BIT
P93580
Bnp Paribas Issuance
BIT
P11YP8
BNP PARIBAS ISSUANCE
BIT
F39402
Vontobel Financial Produ...
BIT
P11FS1
Bnp Paribas Issuance
BIT
F21532
Vontobel Financial Produ...
GATE
LIENETH
lien
AMEX
ZROZ
PIMCO 25 Plus Yr Zero Co...
EU
MLCOT
Coretech 5
EU
OP4E
Ossiam
BIT
F37600
Vontobel Financial Produ...
BIT
P1SEA5
BNP Paribas Issuance
COIN
PETHETH
Pooled Ether
COIN
FLYUSD
TSX
MPVD
Mountain Province Diamonds
BIT
P1DKE6
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有